What is the Historical Analysis of the Quadrivalent Market Size?
The quadrivalent market has seen considerable growth due to a variety of factors.
• In the past years, the size of the quadrivalent market has notably expanded. The market is predicted to escalate from $8.87 billion in 2024 to $9.61 billion in 2025, with a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this growth in the historical period include disease intricacy, educational campaigns, major health occurrences, advancement in healthcare, and technological evolution.
What Is The Projected Growth Of The Quadrivalent Market in the Coming Years?
The Quadrivalent market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the quadrivalent market size is anticipated to witness swift expansion. The market is projected to balloon to $14.22 billion by 2029, maintaining a compound annual growth rate (CAGR) of 10.3%.
The surge during the forecast period is due to worldwide health occurrences, competitive forces, educational drives, modifications in regulations, and changing disease trends. Key trends within the forecast period encompass disease prevalence, regulatory framework, healthcare facilities, consumer knowledge and education, and the competitive scenario.
What Are The Key Drivers Fueling Growth In The Quadrivalent Market?
Chronic and infectious diseases' increasing occurrence is anticipated to drive the quadrivalent market's expansion. Chronic diseases are hereditary and lifestyle-influenced persistent illnesses, while infectious diseases are any health issues caused by an infecting organism such as a bacteria, virus, fungus, or protozoan. Quadrivalent vaccines play a critical role in averting morbidity and mortality from severe infections, and curbing diseases that are not the specific target. Quadrivalent vaccines also prevent chronic (non-communicable) diseases when the root cause is related to carcinogenesis from infectious agents. For instance, a report from the Centers for Disease Control and Prevention, a U.S.-based non-profit organization, stated in September 2024 (Week 37), 0.5% of samples were influenza positive, with 91.4% of them being influenza A and 8.6% influenza B. However, since October 1, 2023 (Week 40), 8.7% of samples were positive on the whole, with 69.2% containing influenza A and 30.8% influenza B. This demonstrates a higher positivity rate overall and a growing ratio of influenza B cases overtime. So, the escalating occurrence of chronic and infectious diseases is catalyzing the quadrivalent market's development.
What Are The Principal Market Segments In The Global Quadrivalent Industry?
The quadrivalent market covered in this report is segmented –
1) By Type: Intradermal Shot, Intramuscular Injection, Nasal Spray
2) By Technology: Conjugated, Live, Inactivated, Recombinant, Toxoid, Other Technologies
3) By Disease: Cancer, Hepatitis, Pneumococcal Disease, COVID-19, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus, Other Diseases
4) By Age Group: Pediatric, Adult
5) By Distribution Channel: Hospital And Pharmacy, Government Suppliers, Other Channels (NGOs)
Subsegments:
1) By Intradermal Shot: Standard Intradermal Injection, Needle-Free Intradermal Delivery
2) By Intramuscular Injection: Standard Intramuscular Injection, Adjuvanted Intramuscular Injection
3) By Nasal Spray: Live Attenuated Nasal Spray, Inactivated Nasal Spray
Pre-Book The Quadrivalent Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Quadrivalent Industry?
The trend of product innovations is noticeably gaining traction within the quadrivalent market. The prime companies in this market have their focus on the creation of innovative solutions, aimed at fortifying their standing. Illustrating this, AstraZeneca – a pharmaceutical firm headquartered in the U.K., debuted their FluMist quadrivalent in September 2022. This Influenza Vaccination Live, Intranasal is an FDA-certified nasal spray flu vaccine catering to individuals aged 2 to 49, and it can be administered without the use of a needle. The vaccine, covered by most health insurance plans and the vaccines for children program, is a live attenuated influenza vaccine (LAIV), and it comes in trivalent or quadrivalent versions.
Who Are the Key Players In The Quadrivalent Market?
Major companies operating in the quadrivalent market include:
• AstraZeneca Plc
• Serum Institute of India Private Limited
• Sanofi S.A.
• GlaxoSmithKline Plc
• CSL Limited
• Bharat Biotech International Limited
• Hualan Biological Engineering Inc.
• Merck & Co. Inc.
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Bio Med Pvt. Ltd.
• Walvax Biotechnology Co. Ltd.
• Chongqing Zhifei Biological Products Co. Ltd.
• Emergent BioSolutions Inc.
• Biological E. Limited
• GSK Biologicals SA
• Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences
• Wuhan Institute of Biological Products Co. Ltd.
• Beijing Tian Tan Biological Products Co. Ltd.
• Shanghai Zhijiang Bio-pharm Co. Ltd.
• Bio Farma
• Butantan Institute
• Pasteur Institute of India
• China National Biotec Group Co. Ltd. (CNBG)
What Are The Regional Insights Into The Quadrivalent Market?
North America was the largest region in the quadrivalent market in 2024. The regions covered in the quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
